The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers

Diabetes Research and Clinical Practice

Volumn 95, Issue 3, 2012, Pages 389-398

  Samaropoulos, Xanthia F ^a,c   Light, Laney ^a   Ambrosius, Walter T ^a   Marcovina, Santica M ^a   Probstfield, Jeffrey ^b   Goff Jr , David C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

ACCORD trial; Adiposity; CVD; Hs CRP; Inflammation; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FENOFIBRATE; HEMOGLOBIN A1C; INTERLEUKIN 6; PLACEBO; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK MANAGEMENT; RISK REDUCTION; WAIST CIRCUMFERENCE;

ADIPOSITY; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMANS; INFLAMMATION; MIDDLE AGED; RISK FACTORS;

EID: 84857238882     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.09.027     Document Type: Article

References (26)

1. Goff D.C., Gerstein H.C., Ginsberg H.N., Cushman W.C., Margolis K.L., Byington R.P., et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardio 2007, 99(12A):4i-20i.
2. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286(3):327-334.
3. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350(14):1387-1397.
4. Lloyd-Jones D.M., Liu K., Tian L., Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 2006, 145(1):35-42.
5. Ndumele C.E., Pradhan A.D., Ridker P.M. Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr 2006, 1(3):190-196.
6. Goldberg R.B. Cytokine and cytokine-like inflammation markers: endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009, 94(9):3171-3182.
7. Rizvi A.A. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci 2009, 338(4):310-318.
8. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006, 97(2A):3A-11A.
9. Swellam M., Sayed M., and M., Abdel-Fatah, Ali A. Clinical implications of adiponectin and inflammatory biomarkers in type 2 diabetes mellitus. Dis Markers 2009, 27(6):269-278.
10. Nguyen N.T., Magno C.P., Lane K.T., Hinojosa M.W., Lane J.S. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008, 207(6):928-934.
11. Farah R., Shurtz-Swirski R., Lapin O. Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment. Cardiovasc Diabetol 2008, 22:7-20.
12. Devaraj S., Rogers J., Jialal I. Statins and biomarkers of inflammation. Curr Atheroscler Rep 2007, 9(1):33-41.
13. Pradhan A.D., Everett B.M., Cook N.R., Rifai N., Ridker P.M. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes. The LANCET Randomized Trial. JAMA 2009, 302(11):1186-1194.
14. Schaumberg D.A., Glynn R.J., Jenkins A.J., Lyons T.J., Rifai N., Manson J.E., et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the Diabetes Control and Complications Trial. Circulation 2005, 111:2446-2453.
15. The ACCORD Study Group Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods. Am J Cardio 2007, 99(12A):21i-33i.
16. Gerstein H.C., Riddle M.C., Kendall D.M., Cohen R.M., Goland R., Feinglos M.N., et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardio 2007, 99(12A):34i-43i.
17. Cushman W.C., Grimm R.H., Cutler J.A., Evans G.W., Capes S., Corson M.A., et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardio 2007, 99(12A):44i-55i.
18. Ginsberg H.N., Bonds D.E., Lovato L.C., Crouse J.R., Elam M.B., Linz P.E., et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardio 2007, 99(12A):56i-67i.
19. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
20. ACCORD Study Group, Cushman W.C., Evans G.W., Byington R.P., Goff D.C., Grimm R.H., et al. Effects of intensive blood pressure control in type 2 diabetes Mellitus. N Engl J Med 2010, 362(17):1575-1585.
21. ACCORD Study Group, Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362(17):1563-1574.
22. Ismail-Beigi F., Craven T., Banerji M.A., Basile J., Calles J., Cohen R.M., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet 2010, 376(9739):419-430.
23. ACORD Study Group, Gerstein H.C., Miller M.E., Genuth S., Ismail-Beigi F., Buse J.B., Goff D.C., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011, 364(9):818-828.
24. Williamson J.D., Miller M.E., Bryan N., Lazar R.M., Coker L.H., Johnson J., et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardio 2007, 99(12A):112i-122i.
25. Cukierman-Yaffe T., Gerstein H.C., Williamson J.D., Lazar R.M., Lovato L., Miller M.E., et al. Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 2009, 32(2):221-226.
26. Aviles-Santa L., Salinas K., Adams-Huet B., Raskin P. Insulin therapy, glycemic control, and cardiovascular risk factors in young Latin Americans with type 2 diabetes mellitus. J Investig Med 2006, 54(1):20-31.